Suppr超能文献

基于 gnomAD 的胚系 TP53 变异体的可变人群流行率估计。

Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.

机构信息

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.

International Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.

出版信息

Hum Mutat. 2019 Jan;40(1):97-105. doi: 10.1002/humu.23673. Epub 2018 Nov 19.

Abstract

Reports of variable cancer penetrance in Li-Fraumeni syndrome (LFS) have raised questions regarding the prevalence of pathogenic germline TP53 variants. We previously reported higher-than-expected population prevalence estimates in sequencing databases composed of individuals unselected for cancer history. This study aimed to expand and further evaluate the prevalence of pathogenic and likely pathogenic germline TP53 variants in the gnomAD dataset (version r2.0.2, n = 138,632). Variants were selected and classified based on our previously published algorithm and compared with alternative estimates based on three different classification databases: ClinVar, HGMD, and the UMD_TP53 database. Conservative prevalence estimates of pathogenic and likely pathogenic TP53 variants were within the range of one carrier in 3,555-5,476 individuals. Less stringent classification increased the approximate prevalence to one carrier in every 400-865 individuals, mainly due to the inclusion of the controvertible p.N235S, p.V31I, and p.R290H variants. This study shows a higher-than-expected population prevalence of pathogenic and likely pathogenic germline TP53 variants even with the most conservative estimates. However, these estimates may not necessarily reflect the prevalence of the classical LFS phenotype, which is based upon family history of cancer. Comprehensive approaches are needed to better understand the interplay of germline TP53 variant classification, prevalence estimates, cancer penetrance, and LFS-associated phenotype.

摘要

Li-Fraumeni 综合征(LFS)中报道的可变癌症外显率引发了关于致病性种系 TP53 变异体流行率的问题。我们之前在由未经癌症史选择的个体组成的测序数据库中报告了高于预期的人群流行率估计值。本研究旨在扩展并进一步评估 gnomAD 数据集(版本 r2.0.2,n=138632)中致病性和可能致病性种系 TP53 变异体的流行率。根据我们之前发表的算法选择和分类变异体,并与基于三个不同分类数据库(ClinVar、HGMD 和 UMD_TP53 数据库)的替代估计值进行比较。致病性和可能致病性 TP53 变异体的保守流行率估计值在每 3555-5476 人中就有 1 个携带者。更严格的分类将近似流行率增加到每 400-865 人中有 1 个携带者,这主要是由于包含有争议的 p.N235S、p.V31I 和 p.R290H 变异体。即使使用最保守的估计值,本研究也显示出致病性和可能致病性种系 TP53 变异体的人群流行率高于预期。然而,这些估计值可能不一定反映基于癌症家族史的经典 LFS 表型的流行率。需要综合方法来更好地理解种系 TP53 变异体分类、流行率估计值、癌症外显率和与 LFS 相关的表型之间的相互作用。

相似文献

5
Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.2019 年 1.1 版李-佛美尼综合征医学指南
Int J Clin Oncol. 2021 Dec;26(12):2161-2178. doi: 10.1007/s10147-021-02011-w. Epub 2021 Oct 11.
10
Evolution of germline TP53 variant classification in children with cancer.胚系 TP53 变异分类在儿童癌症中的演变。
Cancer Genet. 2022 Jun;264-265:29-32. doi: 10.1016/j.cancergen.2022.02.011. Epub 2022 Mar 3.

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验